Replies to post #17165 on Momenta Pharmaceuticals, Inc. (MNTA)

[biocqr]

TEVA > Troubled Teva’s big successor to Copaxone just failed a big PhIII test for multiple sclerosis

https://endpts.com/troubled-tevas-big-successor-to-copaxone-just-failed-a-big-phiii-test-for-multiple-sclerosis/

After years of setbacks, delays and sundry frustrations, a deeply troubled Teva says that a late-stage trial for laquinimod — long billed as a successor to the aging flagship therapy Copaxone for multiple sclerosis — failed the test on the relapsing-remitting form of the disease.

In the meantime, with generic competition looming for Copaxone, Roche recently won an approval for Ocrevus as a new therapy for both relapsing-remitting and primary progressive MS, looking to disrupt a market in which Biogen is seeing revenue begin to wane for Tecfidera.